Tags

Type your tag names separated by a space and hit enter

Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
Contraception. 2006 Dec; 74(6):451-7.C

Abstract

PURPOSE

This randomized multicenter, open-label, trial compared efficacy, acceptability, tolerability and compliance of NuvaRing with a combined oral contraceptive (COC), containing 30 microg of ethinyl estradiol (EE) and 3 mg of drospirenone.

METHOD

In this 13-cycle study, 983 women were randomized and treated (intent-to-treat population) with NuvaRing or COC.

RESULTS

One in-treatment pregnancy occurred with NuvaRing (Pearl Index=0.25) (95% confidence interval [CI]: 0.006, 1.363) and four with the COC (Pearl Index=0.99) (95% CI: 0.269, 2.530). For both groups, compliance (89.2% NuvaRing, 85.5% COC) and satisfaction (84% NuvaRing; 87% COC) were high; the vast majority of women found NuvaRing easy to insert (96%) and remove (97%). Tolerability was similar; the most frequent adverse events with NuvaRing were related to ring use, whereas estrogen-related events were more common with the COC.

CONCLUSION

NuvaRing has comparable efficacy and tolerability to a COC containing 30 microg of EE and 3 mg drospirenone. User acceptability of both methods was high.

Authors+Show Affiliations

Halberstädter Strasse 122, D-39112 Magdeburg, Germany. h.-j.ahrendt@t-online.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17157101

Citation

Ahrendt, Hans-Joachim, et al. "Efficacy, Acceptability and Tolerability of the Combined Contraceptive Ring, NuvaRing, Compared With an Oral Contraceptive Containing 30 Microg of Ethinyl Estradiol and 3 Mg of Drospirenone." Contraception, vol. 74, no. 6, 2006, pp. 451-7.
Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception. 2006;74(6):451-7.
Ahrendt, H. J., Nisand, I., Bastianelli, C., Gómez, M. A., Gemzell-Danielsson, K., Urdl, W., Karskov, B., Oeyen, L., Bitzer, J., Page, G., & Milsom, I. (2006). Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception, 74(6), 451-7.
Ahrendt HJ, et al. Efficacy, Acceptability and Tolerability of the Combined Contraceptive Ring, NuvaRing, Compared With an Oral Contraceptive Containing 30 Microg of Ethinyl Estradiol and 3 Mg of Drospirenone. Contraception. 2006;74(6):451-7. PubMed PMID: 17157101.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. AU - Ahrendt,Hans-Joachim, AU - Nisand,Israel, AU - Bastianelli,Carlo, AU - Gómez,Maria Angeles, AU - Gemzell-Danielsson,Kristina, AU - Urdl,Wolfgang, AU - Karskov,Birgit, AU - Oeyen,Luc, AU - Bitzer,Johannes, AU - Page,Geert, AU - Milsom,Ian, Y1 - 2006/09/27/ PY - 2006/02/10/received PY - 2006/07/25/revised PY - 2006/07/26/accepted PY - 2006/12/13/pubmed PY - 2007/4/18/medline PY - 2006/12/13/entrez SP - 451 EP - 7 JF - Contraception JO - Contraception VL - 74 IS - 6 N2 - PURPOSE: This randomized multicenter, open-label, trial compared efficacy, acceptability, tolerability and compliance of NuvaRing with a combined oral contraceptive (COC), containing 30 microg of ethinyl estradiol (EE) and 3 mg of drospirenone. METHOD: In this 13-cycle study, 983 women were randomized and treated (intent-to-treat population) with NuvaRing or COC. RESULTS: One in-treatment pregnancy occurred with NuvaRing (Pearl Index=0.25) (95% confidence interval [CI]: 0.006, 1.363) and four with the COC (Pearl Index=0.99) (95% CI: 0.269, 2.530). For both groups, compliance (89.2% NuvaRing, 85.5% COC) and satisfaction (84% NuvaRing; 87% COC) were high; the vast majority of women found NuvaRing easy to insert (96%) and remove (97%). Tolerability was similar; the most frequent adverse events with NuvaRing were related to ring use, whereas estrogen-related events were more common with the COC. CONCLUSION: NuvaRing has comparable efficacy and tolerability to a COC containing 30 microg of EE and 3 mg drospirenone. User acceptability of both methods was high. SN - 0010-7824 UR - https://www.unboundmedicine.com/medline/citation/17157101/Efficacy_acceptability_and_tolerability_of_the_combined_contraceptive_ring_NuvaRing_compared_with_an_oral_contraceptive_containing_30_microg_of_ethinyl_estradiol_and_3_mg_of_drospirenone_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0010-7824(06)00308-8 DB - PRIME DP - Unbound Medicine ER -